The pre-sensitive reaction state of 10 severe burn patients after transfusion of 1-3 units of neutrophile granulocyte was investigated. After 3 weeks, almost patients had < 20% positive reaction and only 1/10 of patients had 30% positive reaction. They had received 3 units of neutrophile granulocyte
Burns ; Leukocyte Transfusion ; patients

101 patients with burn sepsis including 22 patients, having peripheral white blood cell count of < 3.109/l treated in the National Institute of Burn, had received 23 units of white blood cells in transfusion. Results showed a decrease of white blood cell count in 58.4% of burn sepsis patients, and an increase in 21.8%. The peripheral white blood cell count was related closely to the germ of sepsis, the state of infections shock and the mortality. The monitoring of white blood cell count has had good impact on early diagnosis and a prognostic significance. The transfusion of white blood cells increases the white blood cell count and promotes its restoration processes
Leukocytes ; Leukocyte Transfusion ; Burns ; Sepsis ; Therapeutics

To evaluate flow-cytometry and Nageotte method for counting residual WBC in thrombocytaphoresis concentrates, their accuracies were determined by dilution studies separately; the repeatability was determined by measuring the interassay coefficient of variation for 14 replicates of a sample with known leukocyte concentration. 102 samples of leukocyte-depleted thrombocytaphoresis concentrates were detected by the above mentioned two methods, and the results were compared each other. The results showed that no difference was observed between two methods over a range of leukocyte concentrations from 0.8 to 10 WBC/microl (P > 0.05). In conclusion, flow-cytometry and Nageotte methods can be used for quality control of WBC-reduced blood components.
Blood Component Transfusion ; Evaluation Studies as Topic ; Flow Cytometry ; Humans ; Leukocyte Count ; methods ; Leukocyte Reduction Procedures ; methods ; Plateletpheresis

Aplastic anemia (AA) is a bone marrow failure disease caused by abnormal activation of T lymphocytes, resulting in the apoptosis of hematopoietic cells and bone marrow failure. Currently, hematopoietic stem cell transplantation (HSCT), immunosuppressive - therapy (IST), and supportive care (e.g. transfusion adjuvant therapy, hematopoietic growth factors, and prevention of infection) are the main treatments of AA. Granulocyte transfusion has recently been accepted as an useful adjuvant therapy of HSCT and intensive IST. This article reported a severe AA patient who failed to respond to IST, but achieved spontaneous remission three times after granulocyte transfusions from related donors. Such cases have rarely been reported. Existence of human leukocyte antigen (HLA) cross between the patient and his relatives may influence the T cell-mediated immunity, which might explain this patient's recovery.
Adult ; Anemia, Aplastic ; immunology ; physiopathology ; therapy ; Granulocytes ; transplantation ; Humans ; Leukocyte Transfusion ; Male ; Remission, Spontaneous

BACKGROUND: Granulocyte transfusion therapy has been used as supportive care for patients with prolonged neutropenia after intensive chemotherapy or peripheral blood stem cell transplantation (PBSCT). Here, we investigated clinical factors of granulocyte transfusion therapy for neutropenic patients with infection to evaluate its efficacy and safety. METHODS: A retrospective analysis of 25 neutropenic patients treated with 99 granulocyte collection and granulocyte transfusion therapy from October 2011 to April 2016 at the National Cancer Center was conducted. Two groups, a count recovery group with a cut off of >1,000/µL and a no recovery group were compared and symptoms related with granulocyte transfusion were analyzed. RESULTS: Granulocyte collection and transfusions were performed in 99 procedures. After granulocyte transfusion therapy, 21 patients (84%) showed count recovery, whereas 4 patients (16%) had no response. Significant differences in pre-absolute neutrophil count (29/µL vs. 0/µL, P=0.048), duration of neutropenia before granulocyte transfusion (11 days vs. 26 days, P=0.011), and total number of granulocyte transfusion (2 times vs. 11 times, P=0.049) were observed between groups. Temporary symptoms related granulocyte transfusion were observed in seven patients (28%); however, all patients showed clinical improvement. The median of the single transfusion volume was 220 mL (200 to 397 mL) and the mean total granulocyte content was 4.92×10¹⁰. CONCLUSION: Granulocyte transfusion therapy is safe and effective for patient with life threatening neutropenia and infection, also considerable for early onset trial for granulocyte transfusion.
Drug Therapy ; Granulocytes* ; Humans ; Leukocyte Transfusion ; Neutropenia* ; Neutrophils ; Peripheral Blood Stem Cell Transplantation ; Retrospective Studies

BACKGROUND: A leukoreduction filter was recently developed in Korea to reduce various kinds of adverse transfusion reactions. The objective of this study was to propose a domestic evaluation system for leukoreduction filters and to apply this evaluation system to assess the newly developed leukoreduction filter. METHODS: We prepared packed red blood cells from 60 units of whole blood (400 mL) collected from 60 normal individuals and evaluated the efficacy of the newly developed filter (FINECELL, KOLON INDUSTRIES, Gumi, Korea) and a control filter (RCM1, Haemonetics, MA, USA). To verify the evaluation system, we assessed the filtration time, residual leukocyte count, RBC recovery, RBC hemolysis, hemoglobin concentration, and hematocrit using a control filter RCM1 and compared the results with those of an evaluation performed by the American Red Cross (ARC) in 2013. We then evaluated the efficacy of the test filter FINECELL using the methods established in this study and compared the results with those of the control filter RCM1. RESULTS: The results of the current study were similar to those of the ARC with the control filters. The test filters developed in Korea were not inferior to commonly used control filters regarding residual leukocyte count, RBC recovery, and RBC hemolysis at 35 days after filtration. All of the results in the evaluation satisfied the international standards. CONCLUSION: These results of this study showed that the efficacy of the newly developed domestic leukoreduction filter were satisfactory and will contribute to improvement of quality of blood components in Korea.
Erythrocytes ; Filtration ; Gyeongsangbuk-do ; Hematocrit ; Hemolysis ; Korea ; Leukocyte Count ; Methods* ; Red Cross ; Transfusion Reaction

BACKGROUND: Performing transarterial chemoembolization (TACE) is difficult with the occurrence of thrombocytopenia in cirrhotic patients with hepatocellular carcinoma (HCC). We aimed to evaluate the long-term efficacy and safety of partial splenic embolization (PSE) combined with TACE in patients with HCC with severe thrombocytopenia related to splenomegaly. METHODS: We conducted a case–control study consisting of 18 HCC patients with severe thrombocytopenia (< 50 × 109/L) who underwent PSE concurrently with TACE (PSE group) and 72 controls who underwent TACE alone (non-PSE group). RESULTS: Mean platelet counts at 1 month and 1, 3, and 5 years after concurrent PSE and TACE significantly increased compared with baseline (all P < 0.05), whereas the platelet count did not significantly increase after TACE alone. In addition, the platelet count at several time points after treatment in the PSE group was significantly higher than that in the non-PSE group, although the baseline platelet count in the PSE group was significantly lower than that in the non-PSE group. The platelet increase after PSE significantly reduced the need for platelet transfusions (P = 0.040) and enabled the subsequent TACE procedures in time (P = 0.046). The leukocyte counts and hemoglobin concentrations after concurrent PSE and TACE were also significantly increased, without deterioration of Child-Turcotte-Pugh score and unexpected side effects. CONCLUSION: PSE combined with TACE is effective in inducing and maintaining long-term thrombocytopenia improvement which reduces the need for the platelet transfusion and helps to perform initial and serial TACE, and is well-tolerated in patients with HCC and thrombocytopenia. PSE may be a promising treatment option for HCC patients with severe thrombocytopenia associated with splenomegaly who will undergo TACE.
Blood Platelets ; Carcinoma, Hepatocellular ; Humans ; Leukocyte Count ; Platelet Count ; Platelet Transfusion ; Splenomegaly ; Thrombocytopenia

The aim of this study was to evaluate the efficacy of intravenous immunoglobulin treatment for recurrent spontaneous abortion. Immunologic causes in either alloimmune or autoimmune type have been suggested for more than 80% of these patients. Various immunotherapy including paternal leukocyte transfusion has been used, but there is controversy on its efficacy and side-effects. The proposed immunomodulatory mechanism of intravenous immunoglobulin includes passive transfer of blocking or anti-idiotype antibody, blockade of Fc receptors, enhancement of supressor T-cell function, down regulation of B cell function. In this study, we used intravenous immunoglobulin for the prevention of spontaneous abortion. Five patients with a history of two or more spontaneous abortions were enrolled in this study. Other etiologic factors such as anatomical, chromosomal, hormonal factors were excluded. Three of them were positive for anti-cardiolipin antibody (ACA). When the pregnancy was diagnosed at about five weeks of gestation, 30 g intravenous immunoglobulin was administered and continued up to 28 weeks with three weeks. Ongoing pregnancy beyond 20 weeks was considered successful. Four among five patients (80%) was successful in maintaining pregnancy now ongoing 20, 31, 33, 39 weeks. One patient with ACA positive had abartion due to anembryonic pregnancy. No adverse reaction was observed during the treatment. From these preliminary data, it is suggested that intravenous immunoglobulin treatment may be effective in maintaining pregnancy in patients with unexplained recurrent spontaneous abortion, Further studies are needed to clarify the its immunomodulatory mechanism and establish a more simplified protocol limiting the use at certain critical period of time.
Abortion, Spontaneous* ; Critical Period (Psychology) ; Down-Regulation ; Female ; Humans ; Immunoglobulins* ; Immunotherapy ; Leukocyte Transfusion ; Pregnancy ; Receptors, Fc ; T-Lymphocytes

This study was undertaken to verify a specific effect of intravenous immunoglobulin treatment on the outcome of pregnancy in the patients with a history of unexplained recurrent spontaneous abortion. Five patients with a history of unexplained recurrent spontaneous abortion were treated with intravenous immunoglobulin during their following pregnancy, as soon as pregnancy was confirmed. When pregnancy was confirmed, women were started with 10 gm of immunoglobulin intravenously which was repeated every 2 weeks and four to six times. One of them experienced termination of pregnancy due to blighted ovum syndrome at 9th weeks of gestation and four patients delivered live births at term. Two of them had experienced cesarean section because of breech presentation and placenta previa respectively, rest of them delivered vaginally without problem. There were no adverse reaction in the study patients. These results imply that intravenous immunoglobulin could be effective on the patients with a history of unexplained recurrent spontaneous abortion, and could be applied to them as an alternative method of allogenic leukocyte transfusion.
Abortion, Spontaneous* ; Breech Presentation ; Cesarean Section ; Female ; Humans ; Immunoglobulins* ; Leukocyte Transfusion ; Live Birth ; Ovum ; Placenta Previa ; Pregnancy

This study was undertaken to verify a specific effect of intravenous immunoglobulin treatment on the outcome of pregnancy in the patients with a history of unexplained recurrent spontaneous abortion. Five patients with a history of unexplained recurrent spontaneous abortion were treated with intravenous immunoglobulin during their following pregnancy, as soon as pregnancy was confirmed. When pregnancy was confirmed, women were started with 10 gm of immunoglobulin intravenously which was repeated every 2 weeks and four to six times. One of them experienced termination of pregnancy due to blighted ovum syndrome at 9th weeks of gestation and four patients delivered live births at term. Two of them had experienced cesarean section because of breech presentation and placenta previa respectively, rest of them delivered vaginally without problem. There were no adverse reaction in the study patients. These results imply that intravenous immunoglobulin could be effective on the patients with a history of unexplained recurrent spontaneous abortion, and could be applied to them as an alternative method of allogenic leukocyte transfusion.
Abortion, Spontaneous* ; Breech Presentation ; Cesarean Section ; Female ; Humans ; Immunoglobulins* ; Leukocyte Transfusion ; Live Birth ; Ovum ; Placenta Previa ; Pregnancy